1. Combination therapy with gemcitabine and docetaxel for patients with metastatic or locally advanced synovial sarcoma met the primary endpoint of 3-month progression-free survival. Evidence Rating Level: 3 (Average) Synovial sarcoma (SS) accounts for 5-10% of all soft tissue sarcomas. SS carries a high risk for local recurrence and metastasis. The median 5-year overall survival